We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 61.50 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 23,744 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
06/4/2016 17:31 | Looks like we may have a 'proper'* Golden Cross on the chart in the next few days. *= 50sma crosses a rising 200sma. | bamboo2 | |
30/3/2016 23:12 | Later in the same meeting, Francisco da Costa was awarded the Jeffrey Borer Heart Valve Outcomes Abstract Award. | bamboo2 | |
30/3/2016 23:01 | From HVS Scientific meeting 17-19 March 2016, presentation by Da Costa. Fresh Decellularized Pulmonary Valve Allografts For Rvot Reconstruction During The Ross Operation - Clinical Outcomes At 10 Years Francisco D. Costa1, Eduardo Balbi, Filho2, Rafael Torres2, Daniele Colatusso1, Claudinei Colatusso1, Allysson Calixto2, Marise Costa1. 1Santa Casa de Curitiba PUCPR, Curitiba, Brazil, 2Instituto de Neurologia e Cardiologia de Curitiba, Curitiba, Brazil. Background: Decellularized allografts are a promising alternative for RVOT reconstruction, however, limited long term data is available in the literature. The aim of this study is to evaluate the long-term clinical, echocardiographic and CT scan results of fresh decellularized pulmonary allografts for RVOT reconstruction during the Ross operation. Methods: Between October 2005 and September 2015, 155 Ross operations were performed using a fresh decellularized pulmonary valve allograft. 121 were male, and mean age was 31 ± 15 years. Forty-eight patients were less than 21 years of age. Conduit dysfunction was defined as any peak gradient greater than 40mmHg or insufficiency grade III or IV. Graft diameter and conduit or leaflet calcification was analyzed by CT scan studies. Mean follow-up was 4.8 years (0.1 - 10 years) and was complete in 95% of the cases. Results: Early mean peak gradient was 10±3 mmHg and at the latest follow-up 15±4 mmHg. Only two patients exhibited a late peak gradient > 40 mmHg. Moderate or severe regurgitation was present in two cases. Freedom from conduit dysfunction at 10 years was 92% (CL95%, 85-99%). Two patients were reoperated due to bacterial endocarditis on the allograft but there was no reoperation due to primary conduit dysfunction. Late CT scan studies revealed preserved allograft diameters with no retraction and minimal or absent calcification in the cusps and/or conduit wall. Conclusions: Fresh decellularized allografts for RVOT reconstruction during the Ross operation are associated with excellent hemodynamic performance and low incidence of conduit dysfunction up to ten years of follow-up. The most striking feature was absence of calcification, even in patients younger than 20 years of age. Our results suggest that decellularized allografts may be superior to conventional cryopreserved allografts, especially in children, adolescents and young adults. | bamboo2 | |
26/3/2016 15:19 | Thanks for the YouTube link, bamboo2, very informative. Also led me to this, which is a good background / overview for new or potential investors: Tissue Regenix Group opened it's (sic) doors to the 'Telegraph Business Club', discussing its patented dCELL technology and the growing need and demand for regenerative medical treatments. | elgordo | |
26/3/2016 12:29 | I can't decide which of these chart patterns is dominant. Co-incidentally the minimum target for the Rounding bottom/bowl [orange] is almost identical to that of the unconfirmed Flag/Pennant. [green] | bamboo2 | |
26/3/2016 12:22 | Antony Odell: European Joint Venture Q&A | bamboo2 | |
24/3/2016 18:53 | Two nice buys at the death today. | luminoso | |
24/3/2016 13:40 | Rayrac - I don't pay on principle as the numpties kept banning me. You're right - they only have so much bandwidth so at busy times you often only get a dew seconds. Sometimes not enough to even see your portfolio ! | igbertsponk | |
24/3/2016 13:29 | The charges have gone up too. | semper vigilans | |
24/3/2016 13:28 | Quiet day all round? Btw, I've been a paying member of advfn for many years, which gives full time viewing of the monitor. I thought it was a waste of my cash, so I'm a freebie now. But I'm finding I get 'timed out' very quickly first thing and later in the afternoon. Am I alone with that, or do you other freebies get the the same treatment? Blackmail comes to mind, but as its their site, they can do what they like. I thought they made enough from adverts to more than cover their costs though? | rayrac | |
23/3/2016 11:55 | Must have been someone adding as price has ticked up again. | igbertsponk | |
23/3/2016 09:32 | Morning to no one in particular. Just thought trades of more than 700,000 before 9.30 was worth a mensch? TRX, CAP-XX and UKOG could help put my portfolio into space before year end.🚀㈻ We shall see no doubt! | rayrac | |
22/3/2016 14:05 | Hi horneblower, I flattened the top channel line and placed more emphasis on making it parallel to the bottom channel line, and admit I did it by eye and not with a ruler, lol; but 40p or 50p, when we get past the resistance at 25p., then we're motoring! And as a longer term investor as opposed to a trader, I look at the fundamentals more too, including the story as well as the numbers; so I'm pretty confidant that this one has a way to go yet. (PS: I'll be happy with 50p. before year end, but as is happening now, that will mean a few hiccups on the way as people take profits.) | andrewbaker | |
22/3/2016 12:50 | New Edison comment. | luminoso | |
22/3/2016 11:15 | Woodford patient trust annual report out today apparently - may make some notice TRX is among the increased positions, who knows. | luminoso | |
21/3/2016 16:42 | Large volume today. it its a large seller, surprised the price has held up so well. | igbertsponk | |
21/3/2016 15:11 | I think this is natural profit taking. My expectation is that we will see a close at 20.75p which is the old support level. | horneblower | |
21/3/2016 14:39 | Trying to seek the truth? Little hiccup on the way up, more news required. | rayrac | |
20/3/2016 12:48 | Now you're just being unkind. | horneblower | |
20/3/2016 12:45 | Gosh! Charting for 40 years, that must make you somewhere in the 70s of age? Got a bit of catching up to do tho' where I'm concerned....somewhe | rayrac | |
19/3/2016 19:06 | Hi bamboo2. Yes, been charting longer than I care to remember - about 40 years I suppose. I'm afraid I use my own systems which may correspond to others' theory...or not. I hope you're right about 40p as, if it goes that strong, I think it will go to my 50p. I'm not bought in yet but expect to be soon. Good luck. | horneblower | |
19/3/2016 14:32 | horneblower, Nice that you seem to have joined us here. Welcome. I don't fully understand your charts but always get the impression they are produced by someone who has been doing this kind of thing for a lot longer than I. I am using Bulkowski's statistics to derive targets based on chart patterns, currently we have a Rounding Bottom or bowl reversal. | bamboo2 | |
19/3/2016 11:42 | Just keeping it in the mind of some. Every post here, gets it onto the FBB. Which I think helps come Monday. So don't be shy, it's a good story! | rayrac | |
18/3/2016 19:38 | For me it's about very interesting buying and even more interesting products/fundermenta Otherwise it wouldn't go anywhere.🚀 | rayrac |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions